STOCK TITAN
  1. Home
  2. News
  3. ATHE

Alterity Therapeutics Ltd - ATHE STOCK NEWS

Welcome to our dedicated news page for Alterity Therapeutics (Ticker: ATHE), a resource for investors and traders seeking the latest updates and insights on Alterity Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alterity Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alterity Therapeutics's position in the market.

News
Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy
Rhea-AI Summary
Alterity Therapeutics (ATH) presented findings from the Biomarkers of progression in Multiple System Atrophy (bioMUSE) Natural History Study at the 34th International Symposium on the Autonomic Nervous System. The study revealed a potential biomarker, N-acetylaspartate (NAA), for assessing disease severity and treatment response in MSA patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.49%
Tags
none
-
News
Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434
Rhea-AI Summary
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced promising new data related to ATH434, a potential treatment for neurodegenerative diseases, presented at the Society for Neuroscience. The study shows ATH434's ability to preserve mitochondrial function and exert direct anti-oxidant activity, highlighting its potential for treating Parkinson's disease and related disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.08%
Tags
none
-
News
Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy
Rhea-AI Summary
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has completed enrolment in its ATH434-201 Phase 2 clinical trial for early-stage multiple system atrophy (MSA), a significant milestone for developing disease modifying treatments for neurodegenerative diseases. The trial, conducted globally, exceeded its enrolment target and is expected to conclude in the fourth quarter of 2024, with results clarifying the path for potential approval of ATH434.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.77%
Tags
clinical trial
News
Appendix 4C – Q1 FY24 Quarterly Cash Flow Report
Rhea-AI Summary
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has made significant developments in the first quarter of FY24. The participant screening for the ATH434-201 Phase 2 study has been closed, and the independent Data Monitoring Committee has recommended the study to continue as planned. The company has received a cash refund of A$4.74M under the Australian R&DTI Scheme. Data presentations from Alterity's bioMUSE natural history study of Multiple System Atrophy were delivered at the International Congress of Parkinson's Disease and Movement Disorders. The company has also been granted a new composition of matter patent by the European Patent Office. Alterity's cash balance on September 30, 2023, was A$16.7M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.05%
Tags
none
-
News
Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder
Rhea-AI Summary
Alterity Therapeutics presented data from its bioMUSE study of Multiple System Atrophy (MSA) at the International Congress of Parkinson’s Disease and Movement Disorders. The presentations highlighted the importance of incorporating biomarkers for accurate diagnosis of MSA. The use of a diverse set of biomarkers was shown to improve diagnostic accuracy in early MSA. Specialized MRI techniques and fluid biomarkers were found to enhance specificity of MSA diagnosis and assess disease severity and treatment response. The findings support the application of clinical and quantitative biomarkers in clinical trials for early MSA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
none
-
News
Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’s
Rhea-AI Summary
Alterity Therapeutics receives new composition of matter patent for iron chaperone drug candidates
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson’s Disease and Movement Disorders
Rhea-AI Summary
Alterity Therapeutics announces poster presentations at International Congress of Parkinson’s Disease and Movement Disorders
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
none
-
News
Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund
Rhea-AI Summary
Alterity Therapeutics has received a A$4.74 million cash refund from the Australian Taxation Office under the Australian Government’s Research and Development Tax Incentive Scheme. The refund relates to eligible research and development activities conducted in the financial year ended 30 June 2022. The funds will be used for Alterity's clinical development and research activities, including Phase 2 clinical trials for ATH434 in Multiple System Atrophy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.1%
Tags
none
-
News
Appendix 4C – Q4 FY23 Quarterly Cash Flow Report
Rhea-AI Summary
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) releases Appendix 4C Quarterly Cash Flow Report and updates on company activities. The ATH434-201 Phase 2 study is on track to complete enrollment in Q3 2023, with top-line data expected by the end of 2024, while ATH434-202 Phase 2 Biomarker study is initiated. Promising wearable sensor data from the bioMUSE Natural History Study was presented at the AAN Annual Meeting. The cash balance on 30 June 2023 was $15.8M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
none
News
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned
Rhea-AI Summary
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced that the ATH434-201 Phase 2 study for the treatment of multiple system atrophy (MSA) will continue as planned. The study is on track to complete enrollment in Q3 2023, with top-line data expected by the end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.5%
Tags
clinical trial
Stock ATHE logo
Alterity Therapeutics Ltd

Nasdaq:ATHE

ATHE Rankings

#5175 Ranked by Market Cap
#4167 Ranked by Stock Gains
N/A Ranked by Dividends

ATHE Stock Data

17.90M
2.54B
1%
0.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Australia
Melbourne

About ATHE

alterity therapeutics limited researches and develops therapeutic drugs for the treatment of parkinsonian's disease and other neurodegenerative diseases in australia. the company's lead drug candidates is ath434 that has completed phase i clinical trial for the treatment of parkinson's disease. it is also developing pbt2 for used as an antimicrobial agent. the company was formerly known as prana biotechnology limited and changed its name to alterity therapeutics limited in april 2019. the company was founded in 1997 and is based in melbourne, australia.